Latest Ristocetin Stories
HOBOKEN, N.J., Aug. 2 /PRNewswire/ -- Octapharma USA has received confirmation of orphan drug exclusivity from the U.S.
LACHEN, Switzerland, Jan. 13 /PRNewswire/ -- Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilateÂ® from the U.S. Food and Drug Administration (FDA).
HOBOKEN, N.J., Dec. 7 /PRNewswire/ -- Octapharma USA today announced the U.S. Food and Drug Administration has approved wilateÂ® for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD).
vW Select Significantly Reduces Laboratory Variability and Provides Clinicians with More Reliable Test Results HORSHAM, Pa., June 30 /PRNewswire/ -- Today, Bio/Data Corporation announced the launch of vW Select(TM), the world's first all-in-one Ristocetin CoFactor Assay.
KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- CSL Behring is providing a $1.2 million grant to fund a first-of-its kind, nationwide study that when completed could serve as the basis for determining optimal prophylaxis treatment for postpartum women with von Willebrand disease (VWD).
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.